Overview

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

Status:
Active, not recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a study to assess the long term safety and tolerability of bimekizumab in subjects with ankylosing spondylitis
Phase:
Phase 2
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.
UCB Biopharma SRL